Jazz to pay $90 million to settle Avadel's US antitrust claims over over Xyrem
MLex Summary: Jazz Pharmaceuticals has agreed to pay $90 million to Avadel to settle US antitrust claims accusing Jazz of abusing the Food and Drug Administration’s regulatory drug approval process to...To view the full article, register now.
Already a subscriber? Click here to view full article